Abstract PR011: Digenic CRISPR screening identifies novel KRAS/FGFR combination therapies for pancreatic cancer
Adaptive signaling remains a major barrier to durable responses with targeted therapy in pancreatic ductal adenocarcinoma (PDAC), where oncogenic KRAS drives the vast majority of tumors. To identify clinically actionable resistance nodes, we developed RAS+, a digenic CRISPR knockout library that systematically interr...